Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT ID: NCT05903833
Last Updated: 2025-09-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
42 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-06-24
Study Completion Date
2029-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT05603910
Recurrent Endometrial Carcinoma
Unresectable Endometrial Carcinoma
RECRUITING
PHASE1
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04781088
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
+4 more
ACTIVE_NOT_RECRUITING
PHASE2
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
NCT07290894
Vulva Cancer
NOT_YET_RECRUITING
PHASE2
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NCT05296512
Ovarian Clear Cell Carcinoma
Gynecologic Cancer
ACTIVE_NOT_RECRUITING
PHASE2
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT05422183
Ovarian Cancer, Epithelial
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A multicenter, single-arm phase II, open-label study, to evaluate the efficacy and safety of pembrolizumab 400 mg Q6W in combination with lenvatinib 20 mg QD in patients with recurrent, persistent, metastatic or locally advanced VSCC not amenable to salvage surgery or definitive (chemo)radiation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Recurrent Vulvar Cancer
Persistent Vulvar Cancer
Metastatic Vulva Cancer
Locally Advanced Vulvar Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment allocation
Administration of pembrolizumab 400 mg Q6W in combination with lenvatinib 20 mg QD
Group Type
EXPERIMENTAL
Pembrolizumab
Intervention Type
DRUG
400 mg Q6W
Lenvatinib
Intervention Type
DRUG
20 mg QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
400 mg Q6W
Intervention Type
DRUG
Lenvatinib
20 mg QD
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed written informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patients awareness and willingness to comply with the study requirements.
2. Female patients who are at least 18 years of age on the day signing informed consent
3. Histologically confirmed locally advanced, recurrent, persistent and/or metastatic VSCC not amenable for salvage surgery or definitive (chemo)radiation (additive palliative radiotherapy for symptom control is allowed)
4. ≤2 previous lines of chemotherapy for recurrent or metastatic disease
5. Measurable disease (investigator assessed RECIST 1.1). Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
6. Have an eastern cooperative oncology group (ECOG) performance status of 0-1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
7. No pregnancy (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] or human chorionic gonadotropin \[hCG\]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG \[or hCG\]), no breastfeeding, and at least one of the following conditions applies:
1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 4 OR
2. A WOCBP who agrees to follow the contraception and pregnancy testing recommendations for investigational medicinal products (IMPs) with demonstrated or suspected human teratogenicity/ fetotoxicity in early pregnancy of the CTFG-guideline in Appendix 4 during the treatment period and for at least 4 months (corresponding to time needed to eliminate pembrolizumab) after the last dose of study treatment. In addition to the described highly effective oral/transdermal contraception methods a barrier method must be used.
A WOCBP should not become pregnant during the treatment and for at least four months.
8. Available archival tumor tissue sample and/or newly obtained core or excisional biopsy of a tumor lesion ideally not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.
9. Adequate organ function as defined in Table 3 of study protocol. Specimens must be collected within 10 days prior to the start of study treatment.
2. Female patients who are at least 18 years of age on the day signing informed consent
3. Histologically confirmed locally advanced, recurrent, persistent and/or metastatic VSCC not amenable for salvage surgery or definitive (chemo)radiation (additive palliative radiotherapy for symptom control is allowed)
4. ≤2 previous lines of chemotherapy for recurrent or metastatic disease
5. Measurable disease (investigator assessed RECIST 1.1). Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
6. Have an eastern cooperative oncology group (ECOG) performance status of 0-1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
7. No pregnancy (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] or human chorionic gonadotropin \[hCG\]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG \[or hCG\]), no breastfeeding, and at least one of the following conditions applies:
1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 4 OR
2. A WOCBP who agrees to follow the contraception and pregnancy testing recommendations for investigational medicinal products (IMPs) with demonstrated or suspected human teratogenicity/ fetotoxicity in early pregnancy of the CTFG-guideline in Appendix 4 during the treatment period and for at least 4 months (corresponding to time needed to eliminate pembrolizumab) after the last dose of study treatment. In addition to the described highly effective oral/transdermal contraception methods a barrier method must be used.
A WOCBP should not become pregnant during the treatment and for at least four months.
8. Available archival tumor tissue sample and/or newly obtained core or excisional biopsy of a tumor lesion ideally not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.
9. Adequate organ function as defined in Table 3 of study protocol. Specimens must be collected within 10 days prior to the start of study treatment.
Exclusion Criteria
1. Non squamous cell histology
2. Contraindications regarding treatment with pembrolizumab:
allergy or hypersensitivity to pembrolizumab or one of the components.
3. Contraindications regarding treatment with lenvatinib: allergy or hypersensitivity to lenvatinib or one of the components or:
1. Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula
2. Radiographic evidence of major blood vessel infiltration
4. Bradyarrhythmia
5. Arterial dissection/aneurysm
6. Long QT Syndrome
7. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 12 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at screening.
8. History or evidence of major thrombotic (e.g. symptomatic pulmonary embolism) or hemorrhagic disorders within 6 months prior to day 1, cycle 1. The degree of tumor invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy.
9. Allogenic tissue/solid organ transplant.
10. Diagnosis of immunodeficiency
11. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
12. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years (time requirement does not apply for definitively treated early endometrial cancer (FIGO IA/B), in-situ carcinomas \[e.g. breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin).
13. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
14. Active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.
15. History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
16. Active infection requiring systematic therapy.
17. Has active hemoptysis within 3 weeks prior to the first dose of study intervention or tumor bleeding within 2 weeks prior randomization.
18. Known history of Human Immunodeficiency Virus (HIV) infection
19. History of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
20. Known history of active TB (Bacillus tuberculosis).
21. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
22. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
23. Pregnancy
24. Breastfeeding Prior/ Concomitant Therapy
25. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
26. Systemic use of corticosteroids or immunosuppressive drugs within 7 days prior start of study treatment (see EC 11.)
* Systemic corticosteroids (at dose higher than 10 mg/day equivalent prednisone); if systemic corticoid use, corticoid must be stopped at least 7 days before study treatment start
* Interferons
* Interleukins
* Live vaccine
Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.
27. Antiarrhythmics of classes Ia and III and other QT-interval prolongation drugs
28. Prior systemic anti-cancer therapy including investigational agents within 4 weeks \[could consider shorter interval for kinase inhibitors or other short half-life drugs\] prior to allocation.
29. Prior radiotherapy within 2 weeks of start of study intervention. Patients must have recovered from radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
30. Not recovered adequately from any toxicity from other anticancer treatment regimens and/or complications from major surgery prior to starting therapy. Note: Withhold lenvatinib for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing.
31. Administration of a live, attenuated vaccine within 30 days prior first dose of study drug. Diagnostic Assessments
32. Uncontrolled blood pressure (Systolic BP \>140 mmHg or diastolic BP \>90 mmHg) in spite of an optimized regimen of antihypertensive medication.
33. Change of anti-HTN (hypertension) medical regimen within 1 week prior to randomization
34. Prolongation of corrected QT interval (QTc interval) \>480 ms
35. Left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).
36. Electrolyte abnormalities that have not been corrected.
37. Subjects having \>1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \<1 g/24 hours. Prior/Concurrent Study Experience
38. Prior enrolment on a clinical study evaluating pembrolizumab and lenvatinib for a carcinoma, regardless of treatment received.
39. Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention. Note: Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
2. Contraindications regarding treatment with pembrolizumab:
allergy or hypersensitivity to pembrolizumab or one of the components.
3. Contraindications regarding treatment with lenvatinib: allergy or hypersensitivity to lenvatinib or one of the components or:
1. Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula
2. Radiographic evidence of major blood vessel infiltration
4. Bradyarrhythmia
5. Arterial dissection/aneurysm
6. Long QT Syndrome
7. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 12 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at screening.
8. History or evidence of major thrombotic (e.g. symptomatic pulmonary embolism) or hemorrhagic disorders within 6 months prior to day 1, cycle 1. The degree of tumor invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy.
9. Allogenic tissue/solid organ transplant.
10. Diagnosis of immunodeficiency
11. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
12. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years (time requirement does not apply for definitively treated early endometrial cancer (FIGO IA/B), in-situ carcinomas \[e.g. breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin).
13. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
14. Active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.
15. History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
16. Active infection requiring systematic therapy.
17. Has active hemoptysis within 3 weeks prior to the first dose of study intervention or tumor bleeding within 2 weeks prior randomization.
18. Known history of Human Immunodeficiency Virus (HIV) infection
19. History of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
20. Known history of active TB (Bacillus tuberculosis).
21. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
22. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
23. Pregnancy
24. Breastfeeding Prior/ Concomitant Therapy
25. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
26. Systemic use of corticosteroids or immunosuppressive drugs within 7 days prior start of study treatment (see EC 11.)
* Systemic corticosteroids (at dose higher than 10 mg/day equivalent prednisone); if systemic corticoid use, corticoid must be stopped at least 7 days before study treatment start
* Interferons
* Interleukins
* Live vaccine
Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.
27. Antiarrhythmics of classes Ia and III and other QT-interval prolongation drugs
28. Prior systemic anti-cancer therapy including investigational agents within 4 weeks \[could consider shorter interval for kinase inhibitors or other short half-life drugs\] prior to allocation.
29. Prior radiotherapy within 2 weeks of start of study intervention. Patients must have recovered from radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
30. Not recovered adequately from any toxicity from other anticancer treatment regimens and/or complications from major surgery prior to starting therapy. Note: Withhold lenvatinib for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing.
31. Administration of a live, attenuated vaccine within 30 days prior first dose of study drug. Diagnostic Assessments
32. Uncontrolled blood pressure (Systolic BP \>140 mmHg or diastolic BP \>90 mmHg) in spite of an optimized regimen of antihypertensive medication.
33. Change of anti-HTN (hypertension) medical regimen within 1 week prior to randomization
34. Prolongation of corrected QT interval (QTc interval) \>480 ms
35. Left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).
36. Electrolyte abnormalities that have not been corrected.
37. Subjects having \>1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \<1 g/24 hours. Prior/Concurrent Study Experience
38. Prior enrolment on a clinical study evaluating pembrolizumab and lenvatinib for a carcinoma, regardless of treatment received.
39. Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention. Note: Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AGO Research GmbH
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linn Wölber, MD PhD
Role: PRINCIPAL_INVESTIGATOR
UKE Hamburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Augsburg
Augsburg, , Germany
Site Status
NOT_YET_RECRUITING
Hochtaunus-Kliniken Bad Homburg
Bad Homburg, , Germany
Site Status
NOT_YET_RECRUITING
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Site Status
NOT_YET_RECRUITING
Universitätsklinikum Düsseldorf
Düsseldorf, , Germany
Site Status
NOT_YET_RECRUITING
KEM Kliniken Essen-Mitte
Essen, , Germany
Site Status
RECRUITING
Universitätsklinikum Essen
Essen, , Germany
Site Status
RECRUITING
Universitätsmedizin Göttingen
Göttingen, , Germany
Site Status
NOT_YET_RECRUITING
University Hospital Hamburg
Hamburg, , Germany
Site Status
RECRUITING
Klinikum Hanau GmbH
Hanau, , Germany
Site Status
RECRUITING
ZAGO - Zentrum für ambulante gynäkologische Onkologie
Krefeld, , Germany
Site Status
NOT_YET_RECRUITING
Universitätsmedizin Mainz
Mainz, , Germany
Site Status
NOT_YET_RECRUITING
Universitätsklinikum Mannheim
Manheim, , Germany
Site Status
NOT_YET_RECRUITING
Klinikum der Universität München, LMU
München, , Germany
Site Status
NOT_YET_RECRUITING
Universitätsklinikum Münster
Münster, , Germany
Site Status
NOT_YET_RECRUITING
University Hospital
Tübingen, , Germany
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Germany
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
http://www.ago-ovar.de/
Homepage of AGO Research GmbH
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-515646-16-00
Identifier Type: OTHER
Identifier Source: secondary_id
AGO-Vulva 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
NCT04519151
RECRUITING
PHASE2
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
NCT05114421
ACTIVE_NOT_RECRUITING
PHASE2
Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
NCT05761132
UNKNOWN
PHASE2
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
NCT03884101
COMPLETED
PHASE3
Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer
NCT06241105
RECRUITING
PHASE2
Lenvatinib in Second Line Endometrial Carcinoma
NCT03005015
WITHDRAWN
PHASE2
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
NCT05147558
ACTIVE_NOT_RECRUITING
PHASE2
Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva
NCT00014599
COMPLETED
PHASE2
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449
COMPLETED
PHASE3
Ribociclib and Letrozole Treatment in Ovarian Cancer
NCT03673124
ACTIVE_NOT_RECRUITING
PHASE2
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05112991
RECRUITING
PHASE2
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
NCT04575961
ACTIVE_NOT_RECRUITING
PHASE2
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
NCT06990516
NOT_YET_RECRUITING
PHASE1/PHASE2
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT03734692
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612
ACTIVE_NOT_RECRUITING
PHASE3
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
NCT03056833
COMPLETED
PHASE1
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
NCT02608684
COMPLETED
PHASE2
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT05263492
TERMINATED
PHASE2
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
NCT06211023
NOT_YET_RECRUITING
PHASE2/PHASE3
Dose-finding Study in Platinum-Resistant Ovarian Cancer
NCT01653912
COMPLETED
PHASE1/PHASE2
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
NCT03197584
WITHDRAWN
PHASE1/PHASE2
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
NCT03989336
COMPLETED
PHASE2
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
NCT00179712
COMPLETED
PHASE1/PHASE2
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
NCT06385548
WITHDRAWN
PHASE1/PHASE2